SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group, Inc.
Your view on SLS
Overview
What the company does, where it operates, and who runs it.
About SELLAS Life Sciences Group, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Angelos M. Stergiou ScD h.c.
- Headquarters
- Times Square Tower, New York City, NY, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Angelos M. Stergiou ScD h.c.
- Headquarters
- Times Square Tower, New York City, NY, US
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States.
Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.
The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer.
It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors.
The company was founded in 2012 and is headquartered in New York, New York.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for SELLAS Life Sciences Group, Inc., and the rating behind it. SLS last traded at $11.54; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for SELLAS Life Sciences Group, Inc.. Starting points for SELLAS Life Sciences Group, Inc.: EPS -$0.17, beta 2.52 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for SELLAS Life Sciences Group, Inc.. SELLAS Life Sciences Group, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for SELLAS Life Sciences Group, Inc.. Trailing twelve-month EPS for SELLAS Life Sciences Group, Inc. stands at -$0.17. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for SELLAS Life Sciences Group, Inc.. SELLAS Life Sciences Group, Inc. has reported as a listed company since 2008. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
SELLAS Life Sciences Group, Inc. valued side by side against its closest peers. SELLAS Life Sciences Group, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold SELLAS Life Sciences Group, Inc., and how their positions are changing. At a $2.15B market value, institutional positions materially move SELLAS Life Sciences Group, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by SELLAS Life Sciences Group, Inc. executives and directors. Shares of SELLAS Life Sciences Group, Inc. have traded between $0.77 and $2.48 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming SELLAS Life Sciences Group, Inc.. SELLAS Life Sciences Group, Inc. is a $2.15B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming SELLAS Life Sciences Group, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for SELLAS Life Sciences Group, Inc.. Coverage tracks SELLAS Life Sciences Group, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.